The FRONT study (NCT04965831) has been initiated to explore the efficacy and safety of the neoadjuvant 8-week plus adjuvant 3-year regimen of furmonertinib for treatment of EGFR-mutated stage IIIA-IIIB resectable NSCLC, while tissue and blood ctDNA monitoring will be performed at multiple time points. This evidence concerns the gene EGFR and non-small cell lung carcinoma.